EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma

Jiayi Yu, Qiang He, Yuting Yan, Kuntong Liu, Rong Xie, Ji Ma, Liang Wang

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-06882-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Jiayi Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Binzhou Medical University, Binzhou, 256603, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Zhongguancun Precision Medicine Foundation's "New Life" Charity Project, the CSCO-Hengrui Oncology Research Fund, the China Health & Medical Development Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the prognostic value of TP53 mutations in patients with diffuse large B-cell lymphoma (DLBCL). We retrospectively analyzed the clinical data and gene sequencing results of 253 newly diagnosed DLBCL. Survival and correlation analyses were performed. We further revealed significant prognostic heterogeneity among different TP53 hotspot mutations, with mutations at codons G245, R175, R273, and R282 indicating a poorer prognosis. Within the DBD, mutations in exons 5, 7, and 8 were associated with poorer PFS, while mutations in exons 5, 6, and 8 were linked to poorer OS. Additionally, mutations in the Loop-L2, Loop-L3, and LSH motifs within the DBD were all significantly associated with unfavorable PFS and OS. Notably, in the cohort treated with R-CHOP plus novel agents (R-CHOP + X), there were no significant differences in response rates or survival between TP53-mutated and TP53 wild-type patients, suggesting this combination may overcome the adverse prognosis associated with TP53 mutations.TP53 mutation is a crucial adverse prognostic factor in DLBCL. Given the significant prognostic heterogeneity among different TP53 hotspot mutations, a more refined risk stratification based on the TP53 mutational profile is warranted in clinical practice. For patients with high-risk mutations, combining R-CHOP with targeted therapies and exploring novel combination strategies targeting specific pathways are recommended. In contrast, standard R-CHOP may remain an appropriate option for patients with low-risk mutations. Future prospective trials are needed to validate the efficacy of R-CHOP combined with targeted agents in TP53-mutated DLBCL to optimize treatment strategies and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseTumor Suppressor Protein p53MutationHumansAntineoplastic Combined Chemotherapy ProtocolsVincristineDoxorubicinPrednisoneCyclophosphamideRituximabPrognosisFemaleRetrospective StudiesAntibodies, Monoclonal, Murine-DerivedAged, 80 and over

Stichwörter der Autor:innen

TP53 mutationDiffuse large b-cell lymphomaNext-generation sequencingPrecision medicinePrognosis

Substanzen

Tumor Suppressor Protein p53VincristineDoxorubicinPrednisoneCyclophosphamideRituximabTP53 protein, humanR-CHOP protocolAntibodies, Monoclonal, Murine-Derived

Autor:innen und Institutionen

  • Binzhou Medical University, Binzhou, 256603, China.
  • Department of Lymphohematology Ward 2, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sci…
  • Clinical Medicine School, Shandong Second Medical University, Shandong, 261000, China.
  • Department of Lymphohematology Ward 2, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. phd_jima@163.com.
  • Binzhou Medical University, Binzhou, 256603, China. wangliang235@gmail.com.

Förderung

  • the Zhongguancun Precision Medicine Foundation's "New Life" Charity Project
  • the CSCO-Hengrui Oncology Research Fund
  • the China Health & Medical Development Foundation

Zitieren

APA

Yu, J., He, Q., Yan, Y., Liu, K., Xie, R., Ma, J., & Wang, L. (2026). Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-026-06882-9

Vancouver

Yu J, He Q, Yan Y, Liu K, Xie R, Ma J, et al. Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma. Annals of Hematology. 2026. doi:10.1007/s00277-026-06882-9

BibTeX
@article{Yu2026,
  author = {Yu, Jiayi and He, Qiang and Yan, Yuting and Liu, Kuntong and Xie, Rong and Ma, Ji and Wang, Liang},
  title = {Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-06882-9}
}
Kostenlos starten →